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Abstract
Background
Chronic hepatitis C (CHC) can be eliminated as a public health threat by meeting the WHO
targets: 90% of patients diagnosed and 80% treated by 2030. To achieve and monitor prog-
ress towards elimination, an updated estimate of the size of the CHC population is needed,
but Denmark has no complete national CHC register. By combining existing registers in 2007,
we estimated the population living with CHC to be 16,888 (0.38% of the adult population).
Aim
To estimate the population living with diagnosed and undiagnosed CHC in Denmark on 31
December 2016. Among additional aims were to estimate the proportion of patients attend-
ing specialised clinical care.
Methods
People with diagnosed CHC were identified from four national registers. The total diagnosed
population was estimated by capture-recapture analysis. The undiagnosed population was
estimated by comparing the register data with data from two cross-sectional surveys.
Results
The population living with diagnosed CHC in Denmark was 7,581 persons (95%CI: 7,416–
12,661) of which 6,116 (81%) were identified in the four registers. The estimated undiagnosed
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fraction was 24%, so the total CHC infected population was 9,975 corresponding to 0.21% of
the adult population (95%CI: 9,758–16,659; 0.21%-0.36%). Only 48% of diagnosed patients
had received specialised clinical care.
Conclusion
CHC prevalence in Denmark is declining and 76% of patients have been diagnosed. Linking
diagnosed patients to care and increasing efforts to test people with former or current drug
use will be necessary to achieve CHC elimination.
Introduction
Chronic hepatitis C (CHC) is a major health problem worldwide, but new treatments have
made elimination possible [1, 2]. The World Health Organization (WHO) has set the ambi-
tious targets of 90% diagnosed and 80% treated by 2030, which was endorsed by all Member
States, including Denmark, in 2016 [3]. In the same year, Denmark also endorsed the action
plan for the health sector response to viral hepatitis in the WHO European Region [4].
Achieving the elimination goal requires knowing the size of the population living with
CHC. This is also a cornerstone in any national elimination plan. However, unlike many coun-
tries in the world, Denmark has not formulated a national viral hepatitis strategy or action
plan.
Denmark is well known for its high coverage national health registers and in 2012, we pub-
lished the first Danish CHC estimate based on four national registers using a capture-recapture
model [5]. This method gives an estimate of a ‘hypothetical’ population which would have
been diagnosed if one or more of the registers included 100% of all diagnosed individuals [6].
We calculated a diagnosed population of 9,166 and estimated the total population (diagnosed
and undiagnosed) living with CHC to be 16,888 (0.38% of the adult population) at the end of
2007. However, due to incomplete reporting to the registers, the total CHC population could
have been as high as 21,468 (0.49%). An update is now urgently needed to plan the CHC elimi-
nation efforts in Denmark. The primary aim of this study was to estimate the population with
diagnosed and undiagnosed CHC in Denmark at the end of 2016. Secondary aims were to
estimate the proportion of patients attending specialised clinical care and the coverage of the
national CHC registers.
Methods
Data sources
We used the same four national source registers as in our previous estimate from 2007 [5].
1. Communicable diseases register: Since May 2000, Denmark has implemented mandatory
reporting of CHC from the diagnosing physician. The CHC case definition is based on the
presence of hepatitis C virus RNA (HCV-RNA). This register is known to have low (<50%)
coverage [7].
2. Hospital register: In 1977, Denmark established the Danish National Patient Registry,
which included all inpatient discharge diagnoses, according to ICD-8 and ICD-10. Since
1995, it also included all hospital outpatient and emergency department visits [8]. We
extracted data on all individuals registered with CHC (ICD-10 diagnosis B18.2). The case
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definition for CHC is not specified. The validity of the register was approximately 67% for
gastroenterology disease diagnoses in 2002 [9]. A 2004 study found that 48% of CHC/HIV
co-infected patients were recorded with a CHC diagnosis in the hospital register [10].
3. Clinical hepatitis database (DANHEP): In 2002, Denmark established the Danish Database
for Hepatitis B and C. It contains detailed information on demographics, test results, treat-
ment status, risk factors, co-morbidities and other relevant information on all chronic hep-
atitis B and CHC patients seen for care in specialised clinics in Denmark. Patients positive
for HCV-RNA in their most recent test were classified as having CHC.
4. Laboratory database (Danvir): Denmark has 18 laboratories performing tests for hepatitis C
[5]. We requested information on all people ever tested for either hepatitis C (antiHCV
or HCV-RNA test) or hepatitis B. The case definition for CHC was positive HCV-RNA at
last test. People with negative HCV-RNA at last test or those only antiHCV positive were
excluded. In contrast to the other three source registers, the laboratory register was not
updated automatically; it is only updated on request from the research team, and not all lab-
oratories provided fully updated data.
For patients present in the source registers, we extracted data from two additional registers:
The Danish civil register: established in 1968 and stores information on vital status, current
place of residence as well as immigration/emigration on all Danish residents [11].
The drug treatment register: established in 1996 and contains information on all persons
treated for drug use in Denmark [12]. This register was used to explore how many people with
diagnosed CHC had been in contact with drug treatment services.
All persons with permanent residence in Denmark are assigned a unique 10-digit personal
identification number (PIN). This number was used to link the information on individuals
from the different registries. The total population in Denmark at the end of 2016 was 5.7 mil-
lion, of which the adult population (�18 years) was 4.6 million (80%) [13].
We identified the individuals who fulfilled the CHC case definition in each register and
excluded those who had died, left Denmark or had an invalid PIN as of 31 December 2016.
We excluded those who had cleared their hepatitis C virus (HCV) infection (i.e. their last
HCV-RNA test was negative and/or they were classified as cured in the clinical database).
Information about cleared infections was only available from the laboratory register and the
clinical database. Therefore, we also excluded patients from the hospital and communicable
disease register if their last registration in these registers were before the date of CHC clearance
in the other registers. We removed patients who were only registered with CHC in the hospital
register but were “non-CHC cases” according to other registers (e.g. they were HCV-RNA
negative or not tested for HCV-RNA and either antiHCV negative or hepatitis B virus positive
in any of the other registers).
The following variables were extracted for all cases as of 31 December 2016: First year of
diagnosis (i.e. first year the person appeared in any of the four registers), age, sex, region of
current residence and treatment for drug use.
Capture-recapture estimation
Assuming independence between the source registers and a common CHC case definition, we
analysed the overlap patterns between the four registers stratified by age (3 groups), sex (2
groups), geographic region (5 groups) and first year of diagnosis (3 groups). As some cells had
too few observations to produce valid estimates, these were analysed without year of diagnosis
to obtain stable estimates. We carried out log-linear modelling using the statistical program
GLIM4 [14] and used the same analytical approach as in 2007 [5, 15]. The final analysis
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contained 113 different models including all possible two-way and three-way interactions fit-
ted to the overlap data. Confidence intervals for the total estimate were derived from bootstrap
analysis of 1000 samples [16].
Estimating the undiagnosed fraction
We used data from two cross-sectional studies to estimate the proportion of undiagnosed
CHC in Denmark:
1. A regional study of older adults (The “3B-study”): Retrospective testing of 4,945 stored
blood samples originally collected between 1998–2000 to investigate Helicobacter pylori
infection [17, 18]. The population tested in this study was 58–83 years old in 2016. The
stored samples were tested for HCV-RNA in 2014.
2. A seroprevalence study of HCV infection among 1,041 people in prison conducted between
2016–2017 where 801 (77%) were tested for HCV-RNA. The study was performed in eight
prisons in the South Region. Participants came from all over Denmark and were represen-
tative of the national prison population. The median age of participants was 30 years, 97%
were male, and 8.5% reported injecting drug use [19].
We investigated if individuals identified with CHC in these two studies were diagnosed
with CHC in any of the source registers and calculated a 95% confidence interval on the esti-
mated undiagnosed fraction.
Sensitivity analyses
To investigate the impact that under-reporting and misclassification of hepatitis cases might
have on our estimate, we performed several sensitivity analyses. We performed three source
capture-recapture analyses to evaluate the effect of excluding one of the four source registers
[20].
In addition, we used a multiple indicator method (MIM) analysis to validate an unrealisti-
cally high estimate for the South Region in the capture-recapture analysis [21]. In this multiple
regression model, the CHC prevalence (per capita) was the dependent variable and the ‘inde-
pendent’ variables were the four source registers. The model with only the hospital register
had the best fit across regions, and this was not improved by including other source registers.
We followed the WHO guidelines for accurate and transparent health estimates reporting
[22]. The study was approved by the Danish Data Protection Agency in 2016 (Journal no: 16/
43190 and 18/52996). Data were fully anonymized prior to analysis. As a register-based study
without contact to patients, informed consent from participants was not required, according
to Danish law. However patients registered in the clinical database (DANHEP) did provide
written consent to have their data used in research prior to registration in the database.
Results
The initial extraction included 1,046,013 individuals, of whom 20,174 were identified as ever
registered as infected with hepatitis C. Of these, 6,380 (32%) had died and 1,188 (6%) did not
have a valid PIN, resulting in 12,606 individuals (62%) being included for further analysis.
Among these, 9,973 (79%) people had ever had a positive HCV-RNA test, including 2,565
(26%) who had cleared their infection (of which 1,604 (63%) had recorded successful CHC
treatment). Excluding patients with past infection left 7408 (74%) patients for further analysis.
Among the 7408 patients the overlap between the four registers varied: most cases were in
all four registers and the second-largest group was those, only present in the hospital register.
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Of 1,681 patients, only in the hospital register, we identified 1,292 who had either negative
antiHCV or HCV-RNA results and/or had chronic hepatitis B (ICD10 code 18.1) with no
signs of HCV co-infection according to the other source registers. We could not check the
clinical records of these patients, but in the “3B-study” with complete laboratory data, 7
patients only diagnosed in the hospital register were all found to be non-CHC cases. We
excluded the 1,292 (17%) non-CHC patients reducing the “Hospital only” group to 388 and
our total captured population to 6,116 (Fig 1).
Among the 6,116 living with CHC, most were identified through the hospital register
(N = 5,080, 83%) and the laboratory database (N = 4,644, 76%) and 60% had attended special-
ised clinical care (Table 1).
The median age was 50 years (with 80% being between 36–64 years) and 65% were male.
Most living with diagnosed CHC were aged between 50–59 years in 2016 (N = 1,938, 32%).
The age at diagnosis had increased with time: the median age of those with first entry in any
register before 2001 was 33 years and increased to 44 years for those diagnosed after 2008. The
majority of cases were among people living in the Capital region (37%) and overall, most peo-
ple (38%) were diagnosed after 2008. More than half (58%) of those with diagnosed CHC had
ever been in treatment for drug use, ranging between 54% in the Capital and 65% in the South
Region.
Capture-recapture results
The capture-recapture analysis suggests that if the registers were not subject to under-report-
ing there would be, in total, 7,581 people (95%CI 7,416–12,661) living with diagnosed CHC in
Denmark. This represents a 17% decrease over 9 years (N = 9,166 diagnosed cases in 2007 [5]).
Fig 1. Overlap pattern between chronic hepatitis C cases in each of the four Danish registers (N = 6,116) after
validation.
https://doi.org/10.1371/journal.pone.0238203.g001
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The total “hidden” diagnosed population was 1,465 (19%) but varied between 6% in the North
and 31% in the South Region (Table 2).
Estimating the fraction with undiagnosed CHC
We used two cross-sectional studies where, in total, N = 12 (the “3B-study”) and N = 34
(prison study) participants respectively tested HCV-RNA positive. Of these, 4 (33%) and 7
(21%) were not found in any of the four source registers and we therefore classified in total
24% (11/46) (95% CI 13%-39%) to have undiagnosed CHC.
Applying this to our estimated 7,581 diagnosed chronic infections resulted in a total esti-
mated population living with CHC (diagnosed plus undiagnosed) of 9,975 (95% CI 9,758–
16,659). This corresponded to a national adult CHC prevalence of 0.22% (95% CI 0.21%-
0.36%), significantly lower than the 0.38% reported in 2007 (p<0.05) [5].
Sensitivity analyses
We addressed several issues in our data:
Firstly, if we had not excluded the 1,292 misclassified CHC cases, the estimated diagnosed
population would be 11,158 (95%CI 10,489–15,630).
Secondly, the major decline in reporting from laboratories after 2010, not mirrored in the
other registers reflects that the laboratory database was not automatically updated (Fig 2).
If reports from the laboratory had continued to follow the hospital register after 2010, then
approximately 700 additional cases would have been reported. A simple three-source capture-
recapture estimate [20] excluding the laboratory register and with no correction for interac-
tions increased the estimated diagnosed population by 24% (N = 1,850), whereas excluding the
hospital register meant an increase of 9% (N = 669).
Thirdly, the South Region had the highest proportion of diagnosed patients not present in
the registers (the hidden population). This was unexpected as this region has been a pioneer in
Table 1. People living with diagnosed chronic hepatitis C in Denmark according to four national registers end 2016 (N = 6,116).
Database Laboratory Comm. Dis Hospital Clinical TOTAL
Chronic hepatitis C 4644 76% 3109 51% 5080 83% 3676 60% 6116 100%
only in one register 538 9% 236 4% 388 6% 116 2% 1278 21%
Sex
Male 3069 66% 2009 65% 3278 65% 2341 64% 3986 65%
Age
<40 700 15% 516 17% 871 17% 682 19% 1052 17%
40–49 1412 30% 990 32% 1451 29% 1067 29% 1795 29%
50+ 2532 55% 1603 52% 2758 54% 1927 52% 3269 53%
Administrative region
North 390 8% 168 5% 397 8% 317 9% 490 8%
Central 782 17% 392 13% 833 16% 680 18% 962 16%
South 1243 27% 910 29% 1183 23% 1002 27% 1595 26%
Zealand 524 11% 480 15% 688 14% 369 10% 825 13%
Capital region 1705 37% 1159 37% 1979 39% 1308 36% 2244 37%
Year of diagnosis
�2000 1462 31% 1000 32% 1487 29% 999 27% 1787 29%
2001–2007 1743 38% 1104 36% 1617 32% 1248 34% 1990 33%
2008–2016 1439 31% 1005 32% 1976 39% 1429 39% 2339 38%
Registered in the drug treatment register 2804 60% 2014 65% 2917 58% 2119 58% 3556 58%
https://doi.org/10.1371/journal.pone.0238203.t001
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outreach hepatitis C testing for decades. Completeness of registers in the South Region is
believed to be high, and “laboratory only” was 14% here compared to 9% in the national esti-
mate (Fig 1). The capture-recapture analyses in the South Region tended to favour more com-
plex models (with more interaction between source registers than the other areas). These
factors could lead to over-estimation. To address this, we adjusted CHC prevalence in the
South using a multiple indicator method (MIM) regression model. This reduced the estimated
diagnosed CHC population in the South from 2,301 to 1,599 (95% CI 1,308–1,890) compared
to 1,595 observed cases, suggesting only 0.2% hidden in the region, an unlikely high reporting
Table 2. Estimated number of people living with chronic hepatitis C (diagnosed and undiagnosed) in Denmark at the end of 2016 (N = 9,975).
North Central South Zealand Capital Denmark 95% CI
n (%) n (%) n (%) n (%) n (%) n (%)
Age
<40 100 (19) 193 (17) 531 (23) 146 (15) 365 (14) 1,335 (18) 1,199–2,996
40–49 136 (26) 329 (29) 811 (35) 267 (27) 707 (27) 2,250 (30) 2,088–3,663
50+ 283 (55) 628 (55) 959 (42) 561 (58) 1,565 (59) 3,996 (53) 3,815–7,199
Sex
Male 342 (66) 756 (66) 1,613 (70) 592 (61) 1,579 (60) 4,882 (64) 4,742–8,127
Year of diagnosis
� 2000 195 (38) 356 (31) 728 (32) 249 (26) 569 (22) 2,097 (28) 1,954–2,290
2001–2007 141 (27) 392 (34) 714 (31) 295 (30) 989 (38) 2,531(33) 2,344–6,316
2008–2016 183 (35) 402 (35) 859 (37) 430 (44) 1,079 (41) 2,953 (39) 2,789–4,994
Total estimated diagnoses 519 (7) 1,150 (15) 2,301 (30) 974 (13) 2,637 (35) 7,581 (100) 7,416–12,661
95% CI 507–619 1,052–2,397 2,044–5,141 929–1,212 2,465–5,232
“Hidden” CHC diagnosesa 29 (6) 188 (16) 706 (31) 149 (15) 393 (15) 1,465 (19) 1,300–6,545
Total CHC populationb 683 1,513 3,028 1,282 3,470 9,975 9,758–16,659
Population prevalencec 0.14% 0.15% 0.31% 0.19% 0.24% 0.22% 0.21%-0.36%
a The “hidden” CHC diagnoses is the main outcome of the capture-recapture analyses and refers to the estimated number of CHC diagnoses not identified due to
incompleteness of the registers (i.e. it is the total estimated diagnoses minus the observed (“captured”) diagnoses).
b Total CHC population: adjustment for 24% undiagnosed.
c Population prevalence: estimated CHC prevalence (diagnosed and undiagnosed) in the adult population.
https://doi.org/10.1371/journal.pone.0238203.t002
Fig 2. Number of new chronic hepatitis C cases reported per year in the four source registers (N = 6,116).
https://doi.org/10.1371/journal.pone.0238203.g002
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rate. If we accept the MIM adjustment for the South, the national estimate would decrease by
9% to 6,879 (95% CI 6,674–10,215).
Fourthly, antiHCV positive patients without a positive HCV-RNA result were excluded.
This reflected that previously, HCV-RNA was only ordered by hospital specialists once the
patient was referred, thus patients tested in drug treatment facilities and primary care, but not
entering specialised care, did not get HCV-RNA tested. In the 2007 study, 62% of antiHCV
positive patients tested with PCR were HCV-RNA positive [5]. Thus by excluding the
antiHCV only patients we underestimated the chronically infected population.
In summary, the sensitivity analysis indicated both under- and over-estimations, and the
point estimate of 9,975 is likely to be a conservative estimate given the limitations of our source
registers.
Combining our results in a national cascade of care showed that 37% of all people living
with CHC in Denmark had attended specialised clinical care (Fig 3).
Discussion
This study estimated the population living with CHC in Denmark to be 9,975 (95% CI 9,758–
16,659) including an undiagnosed fraction of 24%. From 2007 to 2016, the estimated CHC
prevalence fell from 0.38 to 0.21%, and the diagnosed fraction increased from 54% to 76%.
However, comparison is difficult as we did not exclude patients misclassified in the hospital
register in the 2007 estimate. Still we think that using the same registers and capture recapture
methodology makes the observed decline in prevalence over time credible.
One reason for the declining prevalence was a high mortality in the cohort; 32% of all in the
registers exposed to hepatitis C had died. In addition, 10% had been cured of CHC. Another
force driving the reduction in CHC prevalence in Denmark was a low CHC prevalence in
young people who use drugs [23]. Moreover, several studies suggest that fewer young people
inject drugs in later years [12, 19, 23]. The very low CHC prevalence among those younger
than 40 years also suggests a low incidence of new infections. In contrast, the prevalence
among 50+ years has doubled the last 10 years, reflecting an ageing cohort effect.
Our findings are in line with a recent study from England, which estimated the CHC preva-
lence in 2015 to be 0.27% in the adult population and a 10-year decrease of 23% from 2005,
Fig 3. The estimated continuum of care for chronic hepatitis C in Denmark (end 2016).
https://doi.org/10.1371/journal.pone.0238203.g003
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compared to our decrease of 42% from 2007 (0.38%) to 2016 (0.21%) [24]. However, estimates
in England suggest that only 31% of people living with CHC have been diagnosed. Our esti-
mate of the diagnosed proportion (76%) was based on two very small samples ranging between
67–79%, of which only one (the prison study) had national coverage. This is similar to the find-
ings from a recent modelling study which estimated that in 2015 63% of CHC cases in Den-
mark were diagnosed [25]. The general population sample was older than our register cohort
and the prison study participants were younger. Applying the same proportion of undiagnosed
CHC in all regions assumes that the testing coverage and reporting was similar between
regions, but this is unlikely. It is expected that higher test coverage would be found in persons
born 1950–1980 as these birth-cohorts have been the focus for testing in Denmark inspired by
the “baby boomer” testing initiative in the US. On the other hand, the 3B-study was performed
in Funen, a region where the focus on HCV testing has been high, and it is possible that this is
lower in other regions. Our diagnosed proportion was similar to Sweden, where a recent hepa-
titis C survey found that 73% of people who tested antiHCV positive had been previously diag-
nosed [26]. A recent systematic review found that 13 EU/EEA countries had conducted HCV
prevalence surveys with an estimated antiHCV prevalence in the EU/EEA of 1.1% (95% CI
0.9–1.4%) of which an estimated 70% have CHC [27]. In the Netherlands, a CHC prevalence
of 0.16% was found using the workbook method, whereas Ireland and Belgium reported 0.98%
and 0.13% CHC prevalence using residual sera testing [28–30]. However, none of these meth-
ods were directly comparable to our study.
We were surprised to see the variation in prevalence between the different regions, and,
especially the higher prevalence (and larger diagnosed population not in the registers) in
the Southern Region than in the Capital Region. CHC is strongly associated with injecting
drug use and half of the people using drugs in Denmark are believed to live in Copenhagen,
so we would expect a much higher prevalence here than observed. As the South Region
had more focus on testing people who use drugs for HCV, the difference could be
explained by more people tested in the South, where registers were updated until end
2016. However, this would imply a lower hidden population in the South, in contrast to
what our model predicted. This was also suggested by the MIM analysis, although this
resulted in an unrealistically high diagnosed proportion in the South Region (99.8%). So all
things considered, we believe that the hidden population in the Southern Region is likely
over-estimated.
The coverage of the national communicable disease register had risen from 32% in 2007 to
41% in 2016. This still relatively low coverage reflects that the register relies on clinicians
reporting as Denmark is one of few European countries without mandatory laboratory report-
ing for hepatitis C [31].
The proportion of diagnosed patients attending clinical care had risen from 34% (3,065/
9,166) in 2007 to now 48% (3,676/7,581), but still more than half of those living with diagnosed
CHC are not attending specialised care. This suggests that calling in patients not attending
care and offering them treatment could be more cost-effective than increasing screening for
the remaining undiagnosed CHC patients in a low prevalence population like Denmark.
There are a number of weaknesses in our study. Firstly, the basic assumption of indepen-
dence of registers in the capture-recapture analysis was not fulfilled. We used log-linear
modelling including interaction terms between registers to compensate for this, but with only
limited success. Secondly, the case definition was not the same in all registers. Particularly,
in the hospital register, the case definition was probably not always based on HCV-RNA posi-
tivity: patients are usually coded by the discharging doctor or by administrative staff and
HCV-RNA results may not be available at the time of discharge.
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Differences in case definitions will decrease the overlap between registers and inflate the
estimate. We tried to adjust for this by applying another statistical method (MIM), but this
resulted in too low an estimate for the South Region.
Our estimate of the proportion with undiagnosed infection was based on small numbers.
This was because the CHC prevalence was low and general population serological surveys,
which enable assessment of the undiagnosed fraction, are rarely conducted in Denmark. Also,
recent sentinel studies in key populations, like people who inject drugs or migrants from high
prevalence areas, were not available.
A major weakness was that the laboratory register we used was a research database with
incomplete reporting from the participating laboratories. Efforts are currently underway to
implement mandatory laboratory-based reporting of CHC in Denmark, which would simplify
future assessments of the national hepatitis C burden. Finally, we did not consider reinfection
among the cured. However, with only 1,604 successfully treated, this would probably only add
few extra cases.
Conclusion
Our study suggests that the population living with CHC in Denmark in 2016 was 9,975
(9,758–16,659) people and declining. Only 41% had been reported to the national communica-
ble diseases register and less than half had attended specialised care. The relatively large range
on our estimate, highlights the methodological challenges and uncertainties. However, no bet-
ter evidence-based estimate exists and we believe this result can assist the health authorities to
formulate a national elimination plan that can assure that Denmark will fulfil the WHO hepa-
titis C elimination goal by 2030. According to our study, the most urgent initiative will be to
ensure that infected people are linked to care and that treatment is offered to all diagnosed
patients, and this strategy has recently been accepted by the national health authorities (PBC
personal communication). People with current or former drug use constitute the main CHC
population in Denmark and thus addressing the needs of this population will be key to reach
national elimination.
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